Physician profile
Reena Patel
NPI 1487175667
$3,484.65
in general payments reported to CMS, 2019-2025
16 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $342 · 2021: $390 · 2022: $708 · 2023: $355 · 2024: $749 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266 · Entertainment: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,266.25 |
| Entertainment | $161.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $989.08 | 2022-2025 | Infuse, Xiidra, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $865.32 | 2019-2021 | |
| Coopervision INC. | $204.83 | 2022-2025 | Myday Contact Lens |
| Alcon Vision LLC | $199.32 | 2019-2024 | Precision 1 |
| Optos, INC. | $161.29 | 2024-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $137.51 | 2024 | Radius |
| Genzyme Corporation | $122.03 | 2019 | |
| Biotissue Holdings INC. | $120.08 | 2024 | |
| Allergan, INC. | $119.58 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $117.86 | 2019 | |
| Kala Pharmaceuticals, INC. | $110.81 | 2021 | |
| Oyster Point Pharma, INC. | $106.93 | 2024 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $94.71 | 2022 | |
| Novartis Pharmaceuticals Corporation | $69.14 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $38.83 | 2024 | Xdemvy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $27.33 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.